CG Oncology is a privately held oncolytic immunotherapy company focused on developing bladder-saving therapeutics for patients with bladder cancer. At CG Oncology we see a world where urologic cancer patients can benefit from our innovative therapies to live and work with dignity and an enhanced quality of life. Our lead candidate, CG0070, is an intravesically delivered oncolytic immunotherapy agent in a Phase 3 trial for the treatment of BCG-unresponsive non-muscle invasive bladder cancer. CG0070 is also in a Phase 2 study in combination with KEYTRUDA® (pembrolizumab) in the same indication. Other types of bladder cancer are being evaluated with CG0070 in combination with OPDIVO® (nivolumab).
Location: United States, California, Irvine
Employees: 11-50
Total raised: $547M
Founded date: 2010
Investors 5
| Date | Name | Website |
| - | Foresite C... | foresiteca... |
| - | Camford Ca... | camford.co... |
| 09.02.2024 | TCG Crosso... | tcgcrossov... |
| - | DHVC | dh.vc |
| 17.11.2022 | Longitude ... | longitudec... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 25.01.2024 | IPO | $380M | - |
| 17.11.2022 | Series E | $120M | - |
| 14.12.2020 | Series D | $47M | - |
Mentions in press and media 21
| Date | Title | Description | Source |
| 25.01.2024 | Bladder Cancer Therapies Developer Raises $380M in the First... | CG Oncology, a company that turns viruses into cancer therapies, has raised $380 million to fund cli... | medcitynew... |
| 25.01.2024 | Bladder cancer biotech CG Oncology raises $380 million in IP... | CG Oncology, a biotech focused on bladder cancer, raised $380 million in its IPO, pricing 20 million... | axios.com/... |
| 04.01.2024 | Why CG Oncology will be the first test of 2024’s IPO waters... | Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech ne... | statnews.c... |
| 22.05.2023 | Bladder Cancer Diagnostics Market is Estimated to Reach the ... | - | globenewsw... |
| 22.05.2023 | Bladder Cancer Diagnostics Market is Estimated to Reach the ... | Data Bridge Market Research analyzes that the global bladder cancer diagnostics market is expected t... | einpresswi... |
| 18.11.2022 | This 31-year-old CEO says staying focused on one disease was... | Arthur Kuan is the CEO of CG Oncology. CG Oncology This story is available exclusively to Insider su... | businessin... |
| 17.11.2022 | CG Oncology Raises $120M in Series E Financing | CG Oncology, an Irvine, CA-based oncolytic immunotherapy company, raised $120M in Series E funding. ... | finsmes.co... |
| 15.11.2022 | CG Oncology Completes $120M Series E | IRVINE, CA, CG Oncology today announced the close of an oversubscribed $120 million Series E finan... | vcnewsdail... |
| 23.08.2021 | CG Oncology CEO highlights biotech’s oncolytic immunotherapy... | CG Oncology CEO Arthur Kuan talked about the biotech company’s experimental bladder cancer treatment... | medcitynew... |
| 01.02.2021 | Startups see new promise in old insight about viruses to sto... | Photo: Main_sail, Getty Images Promoted This Patient Experience Checklist Is Your Key To Success in ... | medcitynew... |
Show more